A study to validate a method of measurement of dermal blood flow in healthy human volunteers after topical application of allyl isothiocyanate (AITC)
| ISRCTN | ISRCTN97082664 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN97082664 |
| Clinical Trials Information System (CTIS) | 2017-003498-33 |
| Protocol serial number | GE40309 |
| Sponsor | Genentech, Inc |
| Funder | Genentech |
- Submission date
- 25/09/2018
- Registration date
- 08/10/2018
- Last edited
- 07/01/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Other
Plain English summary of protocol
Background and study aims
Allyl Isothiocyanate (AITC) is a compound found in common foods such as mustard and horseradish. It can be dissolved in oil and applied to the skin to activate sensory nerves to produce visible, measurable reactions (such as mild irritation or redness). These reactions are due in part to an increase in blood flow to the areas of AITC application on the skin. The increase in blood flow can be measured using a method called laser speckle contrast imaging. This study aims to develop a method to reliably measure the reactions caused by AITC applied to the skin using laser speckle contrast imaging. If successful, this method can be used in future clinical trials to test the ability of new drugs to reduce these reactions.
Who can participate?
Healthy volunteers of any gender aged 18-65
What does the study involve?
All participants have small volumes of AITC dissolved in mineral oil applied to their forearms during two visits, with a 2-week break between visits. The resulting reactions are examined using laser speckle contrast imaging about 1 week after each visit.
What are the possible benefits and risks of participating?
There is no clinical benefit to this trial. Possible side effects are easily treated and include mild skin redness, blistering, pain, or itching. Pain and itching are not expected to last longer than a few hours, but redness and blistering may take several weeks to subside.
Where is the study run from?
Quotient Clinical, Ltd (UK)
When is the study starting and how long is it expected to run for?
September 2017 to November 2018
Who is funding the study?
Genentech, Inc. (USA)
Who is the main contact?
global-roche-genentech-trials@gene.com, reference study ID GE40309
Contact information
Public
1 DNA Way
South San Francisco
94080
United States of America
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Interventional single-center open-label single-group assignment |
| Secondary study design | Non randomised study |
| Study type | Participant information sheet |
| Scientific title | Exploratory skin challenge study using laser speckle contrast imaging to develop and assess the reproducibility of a method for assessing changes in forearm skin blood flow in healthy human volunteers before and after topical application of allyl isothiocyanate |
| Study objectives | This study aims to demonstrate the safety and reproducibility of a topical challenge method to be used in Phase I clinical trials. |
| Ethics approval(s) | Health and Social Care Research Ethics Committee A, 03/10/2017, Board Number: 17/NI/0183 |
| Health condition(s) or problem(s) studied | Topical application of allyl isothiocyanate |
| Intervention | Allyl Isothiocyanate (AITC) diluted in mineral oil: Participants will receive a small volume of 10% and 15% AITC (25 microliters), to be applied to localized forearm regions defined by small O-rings placed on the skin. AITC will be applied during two visits, with an approximately 2-week washout period between visits. Follow-up will occur approximately 1 week after each visit.The resulting reactions will be examined using laser speckle contrast imaging. |
| Intervention type | Other |
| Primary outcome measure(s) |
Reproducibility across two visits in the change in dermal blood flow after AITC challenge, measured by Laser Speckle Contrast Imaging at visits 1 and 2 |
| Key secondary outcome measure(s) |
1. Percentage of participants with adverse events (AEs), measured from baseline through to the end of the study (up to 24 days) |
| Completion date | 30/11/2018 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 30 |
| Total final enrolment | 23 |
| Key inclusion criteria | 1. Participants must be willing and able to communicate and participate in the whole study 2. Able to sit or lay down for up to 2 hours |
| Key exclusion criteria | 1. Participants who have received any investigational medicinal product (IMP) in a clinical research study within at least 3 months of the first date of skin challenge (Visit 1) 2. Participants who are study site employees, or immediate family members of a study site or sponsor employee 3. Participants who have previously been enrolled in this study 4. History of any drug or alcohol abuse in the past 2 years 5. Regular alcohol consumption in males greater than (>) 21 units per week and females >14 units per week 6. Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 parts per million (ppm) 7. Positive drugs of abuse test result 8. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, or psychiatric disorder, as judged by the investigator 9. History of serious adverse reaction or serious hypersensitivity to the challenge agent (AITC), vehicle (mineral oil), or procedures 10. History of dermatographism 11. Presence of active allergy requiring treatment, as judged by the investigator 12. Presence or history of clinically significant skin disorders, as judged by the investigator 13. History of trauma or surgery to the arm but not including wrist or hand injury/surgery 14. Excessive forearm hair growth, tattoos or other physical or behavioural characteristics that may interfere with the study, as judged by the investigator 15. Participants who are taking, or have taken, any prescribed or over-the-counter drug (other than 4 grams [g] per day paracetamol, hormone replacement therapy and hormonal contraception) in the 7 days before non-investigational medicinal product (AITC) administration 16. Failure to satisfy the investigator of fitness to participate for any other reason |
| Date of first enrolment | 20/10/2017 |
| Date of final enrolment | 22/03/2018 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Nottingham
NG11 6JS
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not expected to be made available |
| IPD sharing plan | Participant-level data will not be available because it is confidential, proprietary information. Study data will be held at Genentech, Inc. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 02/06/2020 | 07/01/2022 | Yes | No | |
| HRA research summary | 28/06/2023 | No | No | ||
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
07/01/2022: Publication reference and total final enrolment.
